CAQ-Derm common mistakes
CAQ-Derm · Understand the traps and how to avoid them.
Reading a morphology description and jumping straight to the diagnosis name without first classifying the primary lesion (macule, papule, plaque, vesicle, pustule, nodule) and its distribution.
Candidates trained on image-heavy resources recognize patterns holistically and skip the analytic step; on a text-only item this shortcut removes the only reliable anchor, so similar-looking entities (e.g., nummular eczema vs tinea corporis vs pityriasis rosea) get conflated.
What to do instead
Before answering, write down three things: primary lesion type, arrangement/distribution, and the single feature that discriminates the top two differentials. Practice by covering the diagnosis in case descriptions and generating the morphology list yourself.
Treating 'biopsy' as the answer whenever the differential is broad, instead of selecting the next best management step the stem is actually testing (e.g., KOH prep, Wood lamp, patch testing, empiric antifungal trial).
Biopsy feels like the safe, definitive choice, and candidates overgeneralize from the few classic 'biopsy is the answer' scenarios. This fails items where a cheap bedside test is diagnostic and faster.
What to do instead
For each inflammatory or infectious differential, memorize the cheapest confirmatory test and its characteristic finding (KOH for hyphae, scraping for scabies mite, Tzanck for multinucleated giant cells, patch test for allergic contact dermatitis). Reserve biopsy for suspected malignancy, atypical eruptions, or conditions where bedside tests are nondiagnostic.
Missing severity red flags in psoriasis and atopic dermatitis, such as erythroderma, generalized pustulation, or ocular/systemic involvement, and choosing a topical regimen when the stem describes a patient who needs urgent systemic therapy or hospitalization.
Candidates focus on naming the disease correctly and stop reading once they recognize it, so the qualifying clause ('fever, diffuse erythema, pustules at the periphery') that changes management goes unweighted.
What to do instead
After identifying the diagnosis, re-read the stem specifically for severity qualifiers and complications. Build a short list per disease of the findings that escalate care (psoriatic erythroderma, generalized pustular psoriasis, eczema herpeticum, ocular involvement in atopic dermatitis) and the immediate next step for each.
Confusing the clinical appearance and behavior of basal cell carcinoma, squamous cell carcinoma, and melanoma, and then selecting the wrong excision margin or referral urgency.
The three share risk factors and sun-exposed locations, and candidates rely on one buzzword ('pearly', 'ulcerated') without linking it to the tumor's biology and the corresponding management pathway.
What to do instead
Build a comparison table with columns for typical lesion description, growth pattern, metastatic potential, preferred biopsy technique, and treatment (electrodesiccation and curettage vs excision vs Mohs vs wide local excision with sentinel node evaluation). Anchor each buzzword to its tumor and to the management consequence.
Applying adult dosing, adult topical potency, or adult treatment duration to pediatric patients with atopic dermatitis or other childhood dermatoses.
Most study material is written around adult presentations, and candidates transfer adult regimens without adjusting for body surface area, thinner pediatric skin, and greater systemic absorption risk.
What to do instead
Memorize the pediatric-specific rules you are likely to be tested on: low-to-medium potency topical corticosteroids for the face and flexures, sparing use of high potency, calcineurin inhibitors as steroid-sparing options, and the fact that most childhood atopic dermatitis improves with emollients plus appropriate topical anti-inflammatory therapy. Review body-surface-area-based dosing for systemic agents.
Misclassifying a drug eruption, such as failing to distinguish morbilliform exanthem from urticaria, fixed drug eruption, or a severe cutaneous adverse reaction (Stevens-Johnson syndrome/toxic epidermal necrolysis, DRESS).
Timing relative to drug initiation is the key discriminator, and candidates often anchor on the drug name rather than on the latency, mucosal involvement, blistering, or eosinophilia described in the stem.
What to do instead
Learn the latency windows (morbilliform typically days to two weeks, DRESS two to eight weeks with eosinophilia and organ involvement, SJS/TEN with mucosal erosions and epidermal detachment) and the immediate action for each. When a stem mentions a new medication, make timing and mucosal/systemic findings your first check.
Overlooking cutaneous signs of systemic disease, treating a rash as primary dermatologic and missing the underlying internal diagnosis (e.g., acanthosis nigricans with insulin resistance or malignancy, erythema nodosum with sarcoidosis or inflammatory bowel disease, dermatomyositis with malignancy).
Candidates compartmentalize dermatology as skin-only and do not systematically screen the stem for systemic clues such as weight loss, myopathy, or gastrointestinal symptoms.
What to do instead
Maintain a 'skin sign to systemic association' list and, for any paraneoplastic or reactive eruption, ask what workup the stem implies. Practice items by naming the associated systemic condition before choosing the skin-directed answer.
Choosing a treatment without accounting for contraindications and monitoring, such as methotrexate in liver disease or pregnancy, isotretinoin without pregnancy prevention, or long-term high-potency steroids on the face without a tapering plan.
Candidates memorize first-line agents by disease but not the safety profile that makes an agent wrong for a specific patient described in the stem.
What to do instead
For each major systemic and topical agent, write the absolute contraindications, required baseline labs, and monitoring schedule. When a stem includes comorbidities or pregnancy status, treat those details as deliberate discriminators and eliminate options that conflict with them.
Misjudging contagiousness and reporting requirements, such as failing to recommend exclusion for a child with impetigo or missing that a suspected case of syphilis or gonorrhea requires public health reporting and partner evaluation.
These facts are scattered across public health and infectious disease material rather than core dermatology texts, so candidates skip them during preparation.
What to do instead
Build a short table of common skin infections with columns for transmission route, exclusion-from-school or work guidance, and reportability. Review it in the final week; items on these points are straightforward once the facts are consolidated.
Answering the diagnosis question when the stem asks for the next step in management, or vice versa, and picking a correct-sounding option that does not match the question asked.
Under time pressure, candidates read the vignette, form a diagnosis, and select the option that confirms it, glossing over the final line of the stem.
What to do instead
Read the last sentence of the stem first to identify the task (diagnosis, next test, treatment, or mechanism), then read the vignette with that task in mind. Before committing, restate the question to yourself and confirm the chosen option answers it directly.